Atkins J M, Mitchell H C, Pettinger W A
Am J Cardiol. 1977 May 26;39(6):802-7. doi: 10.1016/s0002-9149(77)80030-1.
Recent case reports suggest that pulmonary hypertension could be caused by minoxidil, a new potent vasodilating antihypertensive drug. Therefore, we evaluated the incidence and severity of pulmonary hypertension in 110 patients with systemic hypertension. Fourteen patients were treated with minoxidil for 2 to 35 months (mean 19.9 months), 15 were treated with no drugs, and the remaining 81 patients received conventional antihypertensive agents of several types. Pulmonary vascular resistance correlated positively (P is less than 0.05) with systemic vascular resistance. Minoxidil-treated patients with hypertension previously refractory to conventional therapy had slightly lower pulmonary vascular resistance than other hypertensive subjects. There was no correlation between pulmonary vascular resistance and duration of minoxidil therapy or other types of antihypertensive regimens. The positive correlation between pulmonary and systemic vascular resistance suggests the possibility of a causal hypertension relation in the two vascular beds.
近期的病例报告表明，新型强效血管舒张性抗高血压药物米诺地尔可能会引发肺动脉高压。因此，我们评估了110例系统性高血压患者中肺动脉高压的发生率和严重程度。14例患者接受米诺地尔治疗2至35个月（平均19.9个月），15例未接受药物治疗，其余81例患者接受了几种类型的传统抗高血压药物治疗。肺血管阻力与体循环血管阻力呈正相关（P<0.05）。先前对传统治疗难治的高血压患者，接受米诺地尔治疗后，其肺血管阻力略低于其他高血压患者。肺血管阻力与米诺地尔治疗持续时间或其他类型的抗高血压治疗方案之间无相关性。肺血管阻力与体循环血管阻力之间的正相关表明，两个血管床之间可能存在因果关系。
